Abstract
In lung cancer screening with low-dose spiral computed tomography (LDCT), the proportion of stage I disease is 50-85%, and the survival rate for resected stage I disease can exceed 90%, but proof of real benefit in terms of lung cancer mortality reduction must come from the several randomized trials underway in Europe and in the USA. Our purpose is to update the readers on recent progress in medical knowledge in this field.
| Original language | English |
|---|---|
| Journal | Current Opinion in Pulmonary Medicine |
| Volume | 16 |
| Issue number | 4 |
| Pages (from-to) | 301-6 |
| Number of pages | 6 |
| ISSN | 1070-5287 |
| DOIs | |
| Publication status | Published - 2010 |
Keywords
- Cost-Benefit Analysis
- Humans
- Lung Neoplasms
- Mass Screening
- Neoplasm Staging
- Randomized Controlled Trials as Topic
- Risk Factors
- Smoking
- Tomography, Spiral Computed